{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063338","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.166686+00:00","generated_at":"2026-06-08T04:03:25.315529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent Q3 net loss $33.6M; cash runway into 2027 after $300M offering; ALK/ROS1 data positive","bullets":["Net loss of $33.6M ($0.59 per share) for Q3 2023; R&D expenses $29.6M, G&A $9.2M.","Cash, equivalents and marketable securities $413.3M at Sept 30; plus $282M net from Oct 2023 offering, runway to 2027.","Reported preliminary Phase 1 data for NVL-655 (ALK+) showing activity in heavily pre-treated patients with favorable safety.","Initiated Phase 2 registrational cohorts for NVL-520 (ROS1+) at 100 mg daily; data update expected in 2024.","Appointed Perrin Wilson, Ph.D., as SVP of Business Development & Strategy; advancing NVL-330 toward IND."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063338","json":"https://secwatch.observer/filing/0000950170-23-063338.json","markdown":"https://secwatch.observer/filing/0000950170-23-063338.md","text":"https://secwatch.observer/filing/0000950170-23-063338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/0000950170-23-063338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/nuvl-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:03:25.315529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"900a3474a58df9e13a5c4ac87c4ae127611616d7","claim":"Nuvalent, Inc. reported financial results for quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Nuvalent, Inc. announced its financial results for the quarter ended September 30, 2023, and other corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017023063338/0000950170-23-063338-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}